Sturge–Weber Syndrome: A Narrative Review of Clinical Presentation and Updates on Management
Journal of Clinical Medicine · 22.03.2025 · 14 (7) · 2182
DOI: 10.3390/jcm14072182 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.03.2025. Verfasst von Aarnav D Shah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lake Forest Academy, Lake Forest, IL 60045, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sturge–Weber Syndrome (SWS) is a rare neurocutaneous disorder caused by a somatic nonsynonymous mosaic mutation most commonly in the GNAQ gene (G protein guanine Nucleotide-binding protein Alpha subunit q). SWS is characterized by capillary-venous malformations in the brain and eyes and a characteristic facial port wine (PW) birthmark (previously called port wine stain/PWS) in the head/neck region. Clinical manifestations vary and include epilepsy, stroke-like episodes, migraine headaches, cognitive delays, glaucoma, ocular vascular anomalies, heterochromia of the iris, visual field defects, and endocrine disorders like growth hormone deficiency or central hypothyroidism. The pathognomonic findings seen in neuroimaging with magnetic resonance imaging (MRI) include the presence of unilateral intracranial leptomeningeal angiomatosis, typically ipsilateral to the facial birthmark. SWS does not currently have a definitive cure, and management strategies focus on symptomatic management such as anti-seizure medications, limited surgical resection of the epileptogenic tissue or hemispherectomy for cases of drug-resistant epilepsy (DRE), selective photo-thermolysis of the PWS using a pulsed dye laser, and the medical and/or surgical management of glaucoma. In addition to these symptomatic treatments, the use of preventive, modifying, or stabilizing treatments like low-dose aspirin in reducing the frequency and severity of seizures and stroke-like events and the use of newer therapies like cannabidiols and mTOR inhibitors are being reviewed and have shown promising early results. This comprehensive narrative review summarizes the current literature on clinical management strategies, ongoing research studies, and future directions in the diagnosis and management of SWS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lake Forest Academy, Lake Forest, IL 60045, USA.
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
- Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
ORCID-Profile: Priyamvada Tatachar
Zitieren
APA
Shah, A. D., Alexieff, P., & Tatachar, P. (2025). Sturge–Weber Syndrome: A Narrative Review of Clinical Presentation and Updates on Management. Journal of Clinical Medicine, 14(7), 2182. https://doi.org/10.3390/jcm14072182
Vancouver
Shah AD, Alexieff P, Tatachar P. Sturge–Weber Syndrome: A Narrative Review of Clinical Presentation and Updates on Management. Journal of Clinical Medicine. 2025;14(7):2182. doi:10.3390/jcm14072182
BibTeX
@article{Shah2025,
author = {Shah, Aarnav D and Alexieff, Peter and Tatachar, Priyamvada},
title = {Sturge–Weber Syndrome: A Narrative Review of Clinical Presentation and Updates on Management},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {7},
pages = {2182},
doi = {10.3390/jcm14072182}
}
EUVIMED